Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation
After HSCT for refractory MG, most patients achieved sustained disease remission. However, HSCT-related mortality in medically complex MG patients may be high. Prospective studies investigating the efficacy and safety of HSCT in the treatment of refractory MG are warranted.
Authors
- Kareem Jamani (ORCID: https://orcid.org/0000-0001-7612-522X)
- Pierre R. Bourque (ORCID: https://orcid.org/0000-0002-7455-0254)
- Benjamin Béland (ORCID: https://orcid.org/0000-0002-9574-1412)
- C. Elizabeth Pringle
- Christopher Bredeson (ORCID: https://orcid.org/0000-0002-9689-5114)
- Natasha Kekre (ORCID: https://orcid.org/0000-0001-8394-0855)
- Harold Atkins
- Christopher Hahn (ORCID: https://orcid.org/0009-0001-7617-6374)
- Chris White (ORCID: https://orcid.org/0000-0002-7732-2206)
- Michael Kennah
- Jan Storek (ORCID: https://orcid.org/0000-0002-7884-9122)
- David Allan (ORCID: https://orcid.org/0000-0003-3261-8289)
- Liam Quartermain
Institutions
- University of Ottawa (CA)
- University of Calgary (CA)
- Ottawa Hospital (CA)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1002/acn3.52246
- Citations
- 5
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.85